A New Blood Test Could Cut the Nine-Year Diagnostic Wait for Ankylosing Spondylitis

Axial spondyloarthritis, or axSpA, is a chronic autoimmune disease that primarily affects the spine and sacroiliac joints, producing inflammatory back pain that tends to be worse with rest and better with movement. Ankylosing spondylitis is the most well-known form. Despite affecting an estimated 1.4 percent of the adult population, more than double the rate of rheumatoid arthritis, axSpA is routinely missed for years. In North America, the average time between when symptoms begin and when a patient finally receives an accurate diagnosis is nine years. During that window, the disease can quietly progress, causing permanent structural damage to the spine that more timely treatment might have prevented.

The core reason for that delay is a diagnostic problem. Back pain is extraordinarily common, affecting nearly 28 percent of American adults at any given time, and most of it is mechanical in origin: muscle strain, disc problems, postural issues. When inflammatory back pain caused by axSpA shows up in a primary care office, it often looks similar on the surface, and busy clinicians do not always ask the distinguishing questions about morning stiffness, nighttime waking, or improvement with activity that would point toward an autoimmune cause. The blood tests historically available to help, C-reactive protein and the genetic marker HLA-B27, are imperfect tools. CRP is elevated in many conditions and is not disease-specific. HLA-B27 is strongly associated with axSpA in populations of European descent, but its prevalence varies significantly across ethnic groups, limiting its reliability as a universal standalone marker.

A biotech company called Augurex Life Sciences is trying to solve this problem with a blood test called SPINEstat. The test measures autoantibodies directed against the 14-3-3eta protein, a marker Augurex originally worked with in rheumatoid arthritis through an earlier product called JOINTstat. In developing SPINEstat, researchers created a multiplex immunoassay that detects five specific autoantibodies to generate a single score reflecting the probability that a patient has axSpA. Data presented at the American College of Rheumatology's annual meeting showed that the anti-14-3-3eta signature behaves similarly in people with mechanical back pain and in healthy controls, while reliably distinguishing those with axSpA. The test can identify both radiographic axSpA, the more advanced form where bone damage is already visible on imaging, and non-radiographic axSpA, an earlier stage of disease that is especially prone to being missed or dismissed.

The clinical significance of catching non-radiographic disease is substantial. Treatments including biologic drugs that target tumor necrosis factor and interleukin-17 work best when started before structural damage sets in, and earlier diagnosis gives patients access to therapies that can slow or halt progression. The FDA recognized the potential impact of SPINEstat by granting the program a Breakthrough Device Designation, an acknowledgment that the test addresses an area of high unmet medical need and merits an expedited development pathway. The test is already approved as an in-vitro diagnostic in Canada and the United Kingdom under the SPINEstat name, and Augurex has indicated it expects to launch in the United States in 2026. For patients who have spent years rotating through physical therapy, chiropractic visits, and pain management without a clear answer, a blood test that can finally flag inflammatory disease would represent something concrete and actionable at last.